Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.

Archives of virology - 1 Jul 2011

Fokam J, Salpini R, Santoro M M, Cento V, D'Arrigo R, Gori C, Perno C F, Colizzi V, Nanfack A, Gwom L C, Cappelli G, Takou D

Abstract excerpt

Most commercial HIV-1 genotyping assays are hampered by high cost in resource-limited settings. Moreover, their performance might be influenced over time by HIV genetic heterogeneity and evolution. An in-house genotyping protocol was developed, and its sequencing performance and reproducibility were compared to that of ViroSeq™. One hundred ninety plasma samples from HIV-1-infected subjects in Cameroon, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cameroon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Techniques

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to Molecular Sequence Data

Share to Phylogeny

Source

Identifiers

PMID: 21465085
DOI: 10.1007/s00705-011-0982-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.PMID 21465085Read ↗

High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.Semantic proximity Read ↗

Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.Semantic proximity Read ↗

Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.Semantic proximity Read ↗

HIV-1 genetic variability in Cameroon.Semantic proximity Read ↗

Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country.Semantic proximity Read ↗

Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samples.Semantic proximity Read ↗

Evaluation of two bioinformatic algorithms for the interpretation of HIV-1 drug resistance and subtyping in Cameroon: Translational application for ART optimization in low-and middle-income countries.Semantic proximity Read ↗

A cheap and open HIV viral load technique applicable in routine analysis in a resource limited setting with a wide HIV genetic diversity.Semantic proximity Read ↗

A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz.Semantic proximity Read ↗

Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.Semantic proximity Read ↗

Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.Semantic proximity Read ↗

Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeq™ 2.0 genotyping system as a gold standard.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.